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ABSTRACT
Background. The concentration of collagen degradation products in plasma may reflect the process of left 
ventricular remodeling in patients after acute myocardial infarction. The aim of this study was to confirm 
that mean fluorescence lifetime of plasma is decreased in patients with left ventricular systolic dysfunction. 
Patients, materials and methods. The study group consisted of patients treated with primary percutaneous 
coronary intervention for acute myocardial infarction admitted to the Department of Cardiology and Internal 
Medicine at the University Hospital in Bydgoszcz. The overall group comprised of 65 patients. From each 
patient 8 mL of blood was taken to obtain plasma that was used for further examination. The time-resolved 
spectrometer Life Spec II with the sub-nanosecond pulsed 360 nm EPLED® diode was used in order to 
measure fluorescence lifetime of samples. 
Results. Significant differences were observed in mean fluorescence lifetime of plasma between groups 
of patients divided according to brain natriuretic peptide levels. Statistical analysis showed that the 
increase in brain natriuretic peptide level is an independent factor resulting  in the decrease in mean 
fluorescence lifetime.
Conclusions. It seems that plasma concentration of collagen degradation products is closely related to brain 
natriuretic peptide level. However, this experiment confirmed that plasma of patients with potential high proba-
bility of developing left ventricular remodeling is characterized by the decrease in mean fluorescence lifetime.
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Introduction
The improved effectiveness of reperfusion therapy 
with percutaneous coronary intervention (PCI) or throm-
bolysis in individuals with acute myocardial infarction 
(MI) resulted in short-term mortality reduction. This, 
however, leads to increased prevalence of patients 
with left ventricular systolic dysfunction (LVSD) and/or 
heart failure (HF) due to left ventricular remodeling 
(LVR) in the long-term follow-up [1, 2]. The mortality 
and morbidity in patients with LVSD and/or HF after 
MI is high [3–5]. To implement preventive treatment, it 
is of supreme importance to distinguish patients with 
increased risk of LVSD and HF development.
Degradation of cardiac collagen and its re-synthesis 
plays an essential role in remodeling of the left ventri-
cle following MI and in the consecutive development 
of HF. Therefore, markers of collagen turnover are 
tested as biomarkers to determine the ongoing heart 
remodeling [6]. Zannad et al. [7] reported that high 
serum level of procollagen type III amino-terminal pro-
peptide in patients with HF was associated with poor 
outcome. On the other hand, the benefit from spirono-
lactone was associated with higher levels of collagen 
synthesis markers.
Fluorescence spectroscopy is an important and 
widely used technique in physical sciences. Fluores-
cence lifetime (FLT) can be sensitive to a great variety 
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of internal factors defined by the fluorophore structure 
and external factors. A combination of environmental 
sensitivity and parametric independence renders FLT 
as a separate yet complementary method to traditional 
fluorescence intensity measurements [8]. The time 
resolution can be obtained with time-correlated single 
photon counting (TCSPC) [9] which consists in the idea 
that the distribution for emission of a single photon after 
an excitation event yields the actual intensity of all the 
photons emitted as the result of excitation [10]. 
According to the results of our previous unpublished 
in vitro study, the increase  inplasma concentration of 
type III collagen degradation products (CDPs) resulted 
in the decrease in mean FLT (mFLT) of plasma. The aim 
of this study was to confirm our findings in vivo assess-
ing mFLT of plasma in patients with LVSD. 
Materials and methods
Study group
The study population consisted of 65 consecutive 
patients treated with primary PCI for acute MI, admitted 
to the Department of Cardiology and Internal Medicine at 
the University Hospital No. 1 in Bydgoszcz. Each patient 
received a thorough information regarding the study and 
gave a written consent. Study population characteristics 
are displayed in Table 1. The study protocol has been 
approved by the Ethical Committee of Nicolaus Coper-
nicus University. Blood samples (8 mL) for time resolved 
fluorescence spectroscopy (TRFS) examination were tak-
en three days after admission at 8.00 a.m. An additional 
blood sample was sent to Diagnostic Laboratory in the 
University Hospital No. 1 in Bydgoszcz  where plasma 
concentration of brain natriuretic peptide (BNP) was mea-
sured on Architect ci8200 analyzer (Abbott Diagnostics, 
Wiesbaden, Germany). Other laboratory parameters 
were assayed using standardized tests. A standard 
echocardiography measurement was performed in all 
patients. Patients were divided into two groups according 
to qualifications  based on echocardiography results and 
plasma concentrations of BNP. These two criteria were 
applied separately (Tab. 1).
Time-resolved fluorescence spectroscopy
 The time-resolved spectrofluorimeter Life Spec II 
(Edinburgh Instruments Ltd, United Kingdom) with the 
sub-nanosecond pulsed EPLED® diode emitting light 
of the wavelength l = 360 nm was used in order to 
measure FLT of samples. The spectrofluorimeter was 
equipped with electronically cooled photomultiplier 
Hamamatsu R928 connected with TCC900 PC Card, 
which incorporates all the electronic modules required 
for TCSPC. The measurements were carried out with the 
use of quartz 3.5 × 10 mm cuvettes at room tempera-
ture. Exposure time of samples  amounted to 300 sec-
onds. Collagen was excited by light of the wavelength 
l = 360 nm, showing strong emission at l = 450 nm. 
Measurements at this excitation wavelength allow the 
decrease in the contribution of different components, 
especially tryptophan-rich proteins, which have the 
maximum absorption at l = 270–290 nm [11].
Statistical analysis
The preliminary step of the analysis was the 
Shapiro-Wilk test of normality of the distribution of 
all measured parameters inside each patient group 
selected according to the  specified criteria. Due to 
the non-normality of the most analysed variables, the 
Mann-Whitney-Wilcoxon (MWW) unpaired rank sum 
tests were used for the comparisons between two 
groups. Therefore, if the variables were normally distrib-
uted, p-values achieved in Student’s t-test were given. 
The dependence between mFLT and clinical character-
istics of patients  was determined by Spearman’s rank 
correlation coefficients (r values). Categorical variables 
were expressed as a number of patients presenting the 
given feature in the analysed group, including mFLT 
of plasma, gel electrophoresis of proteins results, lipid 
profile, echocardiography results and biochemical 
parameters. Differences were considered as significant 
at p < 0.05. P values between 0.05 and 0.10 were 
considered as a trend towards significance. In order to 
establish independent factors which have an influence 
on the mFLT of plasma, the analysis of multiple regres-
sion was obtained. The statistical analysis was carried 
out using the MATLAB® tools and confirmed with the 
use of other statistical packages (Statistica®, SPSS®). 
Results
We applied the TRFS method in search of the charac-
teristic plasma fluorescence resulting in the combination of 
plasma proteins (including products of collagen degrada-
tion) specific for heart dysfunction defined on the basis of 
left ventricular ejection fraction (LVEF) assessed by echo-
cardiography or plasma concentration of BNP in patients 
hospitalized for acute MI (Tab. 1). The analysis showed that 
BNP concentrations were significantly higher in patients 
with lower LVEF. As one could expect, patients grouped 
according to the LVEF exhibit significant differences in 
other (but not all) echocardiographic parameters. How-
ever, a statistically important difference among the mean 
triglycerides concentrations was also observed. It is inter-
esting that higher triglyceride levels occurred in patients 
with LVEF > 40%. On the other hand, when concentration 
of BNP was applied as a grouping criterion, significant 
differences were found in left ventricular end-diastolic 
22
folia Medica copernicana 2014, vol. 2, no. 4
www.fmc.viamedica.pl
diameters (LVEDd) and plasma concentrations of albumin, 
a1 globulin, total protein and C-reactive protein (CRP).
Patients with lower LVEF as well as those with 
higher concentration of BNP were characterized with 
a tendency to have shorter plasma mFLT. A statisti-
cally important difference was obtained for diluted 
plasma and BNP level taken as a discriminating 
variable (Tab. 2).
Table 1. Clinical characteristics of the study population divided into groups according to EF and BNP
LVEF > 40% LVEF ≤ 40% p BNP < 200 pg/mL BNP ≥ 200 pg/mL p
N M p (SW) N M p (SW) N M p (SW) N M p (SW)
Albumin [g/dL] 41 3.68 0.004 23 3.55 0.585 0.127 34 3.86 0.678 30 3.38 0.038 0.000
a1 glob [g/dL] 41 0.34 0.000 23 0.33 0.221 0.806 34 0.31 0.263 30 0.36 0.000 0.027
a2 glob [g/dL] 41 0.78 0.471 23 0.79 0.001 0.850 34 0.79 0.000 30 0.78 0.798 0.623
b1 glob [g/dL] 41 0.42 0.030 23 0.41 0.059 0.556 34 0.43 0.112 30 0.40 0.032 0.057
b2 glob [g/dL] 41 0.38 0.000 23 0.37 0.835 0.769 34 0.38 0.000 30 0.37 0.854 0.920
g glob [g/dL] 41 0.95 0.000 23 1.07 0.002 0.081 34 0.97 0.129 30 1.02 0.000 0.861
Total protein  
[g/dL]
41 6.55 0.203 23 6.53 0.793 0.899* 34 6.74 0.249 30 6.32 0.078 0.012*
BNP [pg/mL] 41 263.78 0.000 23 1268.23 0.000 0.017 34 85.36 0.575 30 1236.06 0.000 0.000
CK MB [U/L] 11 23.91 0.001 12 23.58 0.565 1.000 12 22.42 0.001 11 25.18 0.702 0.478
CK [U/L] 32 140.72 0.000 14 172.79 0.002 0.659 25 137.00 0.000 21 166.52 0.002 0.467
CRP [mg/L] 41 24.03 0.000 23 30.10 0.000 0.433 34 19.46 0.000 30 33.86 0.000 0.019
Ttrop I [ng/mL] 41 3.31 0.000 23 4.97 0.000 0.900 34 3.49 0.000 30 4.38 0.000 0.276
LVESd [mm] 24 34.54 0.314 13 46.77 0.184 0.000* 18 37.11 0.156 18 40.67 0.126 0.259*
LVEDd [mm] 38 47.03 0.406 21 55.62 0.620 0.000* 30 47.83 0.087 28 52.32 0.875 0.024*
LA [mm] 40 40.23 0.283 21 43.10 0.837 0.036* 31 40.94 0.451 29 41.66 0.605 0.590*
Aorta [mm] 38 32.53 0.645 20 34.40 0.233 0.027* 29 32.86 0.624 28 33.43 0.335 0.496*
RVEDd [mm] 36 26.08 0.221 21 27.86 0.012 0.215 28 25.96 0.814 28 27.61 0.005 0.276
IVSd [mm] 38 12.55 0.012 21 12.81 0.047 0.723 30 12.43 0.005 28 12.86 0.168 0.306
PWd [mm] 38 11.66 0.009 21 11.76 0.087 0.581 30 11.67 0.012 28 11.71 0.026 0.673
LVMI [g/m2] 22 134.46 0.345 11 166.64 0.731 0.012* 24 139.46 0.254 9 160.44 0.562 0.134*
LVM [g] 31 250.36 0.847 17 347.35 0.779 0.000* 28 267.32 0.443 19 307.16 0.328 0.115*
LVEF (%) 41 47.88 0.000 22 31.68 0.024 0.000 33 44.52 0.030 29 39.34 0.299 0.071
TC [mg/dL] 35 197.63 0.120 17 185.06 0.974 0.520* 27 209.59 0.059 25 176.16 0.542 0.090
HDL-C [mg/dL] 35 45.00 0.525 17 45.59 0.776 0.875* 27 44.81 0.006 25 45.60 0.813 0.389
LDL-C [mg/dL] 29 116.41 0.090 17 122.00 0.335 0.918 22 132.86 0.281 24 105.29 0.136 0.080*
TG [mg/dL] 34 136.44 0.000 16 86.63 0.033 0.027 25 140.68 0.000 25 100.32 0.096 0.273
Age 42 67.50 0.844 23 69.22 0.136 0.564* 34 65.26 0.922 30 71.60 0.034 0.009
*Student’s t-test was applied, because of the normal distribution
a1 glob — a1 globulins; a2 glob — a2 globulins; b1 glob — b1 globulins; b2 glob — b2 globulins; g glob — g globulins; BNP — brain natriuretic peptide; 
CK MB — creatine kinase MB isoform; CK — creatine kinase; CRP — C-reactive protein; Trop I — troponin I; BMI — body mass index; BSA — body 
surface area; LVESd — left ventricular end-systolic diameter; LVEDd — left ventricular end-diastolic diameter; LA — left atrium; RVEDd — right ventricular 
end-diastolic diameter; IVSd — intraventricular septum diastolic diameter; PWd — posterior wall diastolic diameter; LVMI — left ventricular mass index; 
LVM — left ventricular mass; LVEF — left ventricle ejection fraction; TC — total cholesterol; HDL-C — high-density lipoprotein cholesterol; LDL-C — low-density 
lipoprotein cholesterol; TG — triglycerides; N — number of results included in the measurements; M — mediana; p(SW) — results from Shapiro-Wilk test 
Table 2. Mean FLT in patients divided into groups according to EF and BNP
LVEF > 40% LVEF ≤ 40% p BNP <  
200 pg/mL
BNP ≥ 200 pg/mL p
N M p (SW) N M p (SW) N M p (SW) N M P (SW)
Mean FLT [ns] 42 6.78 0.003 23 6.43 0.832 0.071 34 6.85 0.012 30 6.46 0.252 0.091
Mean FLT 
(diluted) [ns]
42 7.31 0.009 23 6.97 0.200 0.300 34 7.40 0.001 30 6.98 0.915 0.031
*=Student’s t-test was applied. because of the normal distribution
Mean FLT — mean fluorescence lifetime of plasma; mean FLT (diluted — mean fluorescence lifetime of diluted plasma (2:50); BNP — brain natriuretic 
peptide; LVEF — left ventricle ejection fraction; N — number of results included in the measurements; M —mediana; p(SW) — results from Shapiro-Wilk test
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Table 3. Correlations between mean FLT of plasma and 
clinical parameters
Clinical 
parameters
Mean FLT [ns] Mean FLT 
(diluted) [ns]
Albumin [g/dL] p  =  0.387
p  =  0.002
p  =  0.319
p  =  0.010
a1 glob [g/dL] p  = –0.185
p  =  0.144
p  =  –0.161
p = 0.205
a2 glob [g/dL] p  =  0.210
p  =  0.096
p = 0.226
p = 0.073
b1 glob [g/dL] p  =  0.363
p  =  0.003
p = 0.297
p = 0.017
b2 glob [g/dL] p  =  –0.096
p  =  0.439
p = –0.139
p = 0.275
g glob [g/dL] p = –0.136
p = 0.284
p = –0.176
p = 0.165
Total protein [g/dL] p = 0.231
p = 0.067
p = 0.181
p = 0.153
BNP [pg/mL] p = –0.406
p = 0.001
p = –0.376
p = 0.002
CK MB [U/L] p = –0.257
p = 0.237
p = –0.119
p = 0.587
CK [U/L] p = 0.177
p = 0.239
p = 0.157
p = 0.299
CRP [mg/L] p = –0.274
p = 0.029
p = –0.185
p = 0.145
Trop I [ng/mL] p = 0.121
p = 0.341
p = 0.183
p = 0.147
LVESd [mm] p = –0.199
p = 0.212
p = –0.206
p = 0.195
LVEDd [mm] p = –0.160
p = 0.211
p = –0.186
p = 0.145
RVEDd [mm] p = –0.215
p = 0.095
p = –0.149
p = 0.251
IVSd [mm] p = 0.132
p = 0.302
p = 0.236
p = 0.062
PWd [mm] p = 0.031
p = 0.808
p = 0.157
p = 0.219
LVMI [g/m2] p = –0.066
p = 0.707
p = –0.130
p = 0.455
LVM [g] p = –0.47
p = 0.742
p = –0.004
p = 0.977
LVEF (%) p = 0.327
p = 0.007
p = 0.261
p = 0.033
TC [mg/dL] p = 0.404
p = 0.003
p = 0.425
p = 0.002
HDL-C [mg/dL] p = –0.009
p = 0.952
p = –0.035
p = 0.805
LDL-C [mg/dL] p = 0.303
p = 0.040
p = 0.353
p = 0.016
TG [mg/dL] p = 0.392
p = 0.005
p = 0.313
p = 0.027
Mean FLT — mean fluorescence lifetime of plasma; mean FLT (di-
luted) — mean fluorescence lifetime of diluted plasma (2:50);  
a1 glob — a1 globulins; a2 glob — a2 globulins; b1 glob — b1 globulins; 
b2 glob — b2 globulins; g glob — g globulins; BNP — brain natriuretic 
peptide; CK MB — creatine kinase MB isoform; CK — creatine kinase; 
CRP — C-reactive protein; trop I — troponin I; LVESd — left ven-
tricular end-systolic diameter; LVEDd — left ventricular end-diastolic 
diameter; LA — left atrium; RVEDd — right ventricular end-diastolic 
diameter; IVSd — intraventricular septum diastolic diameter; PWd  
— posterior wall diastolic diameter; LVMI — left ventricular mass index; 
LVM — left ventricular mass; LVEF — left ventricle ejection fraction; 
TC — total cholesterol; HDL-C — high-density lipoprotein cholesterol; 
LDL-C — low-density lipoprotein cholesterol; TG — triglycerides
The analysis of correlations between mFLT and clin-
ical parameters was performed in all patients (Tab. 3). 
Significant correlations for albumin, b1 globulin, BNP, 
body mass index (BMI), body surface area (BSA), 
LVEF, total cholesterol (TC), low-density lipoprotein 
cholesterol (LDL-C) and triglycerides (TG) were found 
in both plasma and diluted plasma. However, for CRP 
the correlation with mFLT was revealed only in plasma.
In the context of our research, it is crucial to point 
out the moderate negative correlation between mFLT 
and BNP values (Fig. 1). In the case of mFLT obtained 
for diluted plasma, the correlation with BNP level slight-
ly decreases but the trend remains the same — the 
increase in BNP concentration is associated with the 
decrease in mFLT. 
According to the analysis of multiple regression, 
concentrations of b1 globulins, troponin I and BNP are 
the only independent factors affecting the mFLT that 
reach statistical significance. The optimal regression 
model for mFLT of plasma can be expressed by the 
following equation:
The p-values of these variables were pb1g = 0,0009, 
ptI = 0,0438, pBNP = 0,0121, respectively. The coef-
ficient of determination (R2) of the model was 0,419; 
p = 0,00006. This model explains 42% of variability of 
the mFLT of plasma.
Discussion
According to our research, TRFS is a promising 
method for plasma assessment which allows screening 
for different diseases, including those with concomi-
tant increase in CDPs concentration. Iraqi et al. [12] 
demonstrated usefulness of CDPs assessment in short- 
and long-term follow-up after MI. The combination of 
increased concentrations of CDPs and BNP was asso-
ciated with all-cause mortality and the composite end 
point of cardiovascular death or HF hospitalization, with 
hazard ratios of 2.49 (p = 0.039) and 3.03 (p = 0.002), 
respectively. Moreover, during follow-up the concentra-
tion of CPDs was consistently lower in patients treated 
with eplerenone. The long-term kinetics of biomarkers 
of collagen synthesis and degradation suggests that 
extracellular matrix (ECM) remodeling is an active 
process in patients with acute MI with left ventricular 
dysfunction and congestive HF [12]. 
The BNP is secreted by the left ventricle in response 
to mechanical wall stress and is involved in cardiac 
remodeling [13]. It has been suggested that BNP level 
may have an essential role in screening for LVSD in 
patients after acute MI [14, 15]. The concentration of 
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Figure 1. Correlations between mean FLT [ns] and BNP [pg/mL] in plasma (A) and diluted plasma (B)
plasma BNP increases in proportion to the size of the in-
fract, after acute MI [16–18]. Xueyan et al. [19] observed 
the significant negative correlation between LVEF and 
BNP level. They also presented the significant differ-
ence of BNP concentration in patients with severe HF 
between baseline and after treatment. Wang et al. [20] 
suggested that high serum concentrations of BNP are 
associated with poor outcomes.
We observed significant differences in mFLT of 
plasma between groups of patients divided according 
to BNP levels. Moderate negative correlation was also 
revealed between concentration of BNP and mFLT 
of plasma in patients after MI. A multiple regression 
analysis confirmed that the increase  in BNP level is an 
independent factor resulting in the decrease in mFLT. 
The data obtained from this observational study are 
in line with the results of our previously performed in 
vitro experiment showing the decrease  in mFLT with 
increasing concentrations of type III CDPs (unpublished 
data). Both of these studies suggest that plasma of 
patients with potential high probability of developing 
LVR is characterized by the decrease in mFLT.
Study limitations
Some other factors, except for BNP, may have an 
influence on mFLT. Therefore, additional methods 
should be applied to distinguish patients with the in-
creased level of CDPs. In further studies, it is essential 
to eliminate the majority of unnecessary particles from 
plasma just before the final measurement. Probably, 
the special membranes with specific diameter, such as 
those eliminating albumins, will be the simplest method. 
Albumin, which is the main protein in the human blood 
plasma, [21] has a molecular weight much bigger than 
CDPs  and elimination of this protein removes about 
50% of the human plasma proteins. It is crucial to con-
tinue further investigation in this field. 
Conclusion
Having taken into account the experimental data, 
we assumed that plasma concentration of CPDs is 
closely related to BNP level. This experiment confirmed 
that plasma of patients with potential high probability 
of developing LVR is characterized by the decrease 
in mFLT. 
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